# Pea Protein Muscle Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/pea-protein-muscle-meta-analysis-evidence-review
Category: evidence-review
Summary: Pea Protein Muscle Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed 
Last reviewed: 2026-06-14
Reviewed by: Migaku Evidence Review
# Pea Protein Muscle Meta-analysis: What the Evidence Says

## Quick Answer

Pea Protein Muscle Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation | narrative review | 3 | 2026-05-17 | 10.3390/ph19050786 |
| Branched-chain amino acids from plants and the metabolic syndrome: pathways and pharmacological applications | narrative review | 3 | 2026-05-05 | 10.3389/fnut.2026.1805807 |

## What The Sources Report

- Worldwide, obesity is a major public health problem associated with increased morbidity and mortality for all-causes. [Coluzzi Flaminia (2026); evidence level 3]
- Although obesity is recognized as a high-risk condition for the development of other chronic degenerative non-communicable diseases, this pathology has been declared as a disease per se that leads to a reduction in the quality and expectancy of life. [Coluzzi Flaminia (2026); evidence level 3]
- According to the internationally used definition, MetS is characterized by having at least three out of several possible risk factors, including high blood pressure, hypertriglyceridemia, low levels of HDL cholesterol, elevated fasting glucose, and central obesity. [Wang Song-nan (2026); evidence level 3]
- α p p 6 7 9 9 10 6 High levels of TNF-, IL-6, and CRP are associated with insulin resistance, endothelial dysfunction, and atherogenesis (,,). [Wang Song-nan (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For pea protein muscle meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Coluzzi Flaminia (2026). New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation. DOI: 10.3390/ph19050786. PMCID: PMC13210036. PMID: 42198460. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13210036/
- Wang Song-nan (2026). Branched-chain amino acids from plants and the metabolic syndrome: pathways and pharmacological applications. DOI: 10.3389/fnut.2026.1805807. PMCID: PMC13183640. PMID: 42163964. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13183640/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.